BioWorld MedTech

June 15, 2011

CerebralRx enters market with vagus nerve stimulation device

CerebralRx, a newly formed spin-off of BioControl Medical (both Yehud, Israel), is hitting the ground running with the launch of its FitNeS vagus nerve stimulation system for epilepsy in Europe. (Medical Device Daily) Read More

Washington roundup: FDA's new nanoscale materials guidance sets bar at 1,000 nm

International report: Medical Care Technologies expands Chinese operations

Device gives hospitals early sense of patient's condition

Financings roundup: UHS to offer $175M of second lien toggle notes

Med-Tech Notes

Agreements/contracts: pSivida amends glaucoma R&D development with Pfizer

HIT roundup: Premier releases PhysicianFocus for performance improvement

Patent watch: Biomoda expands use of assay with new patent

Grants roundup: Precision Medical receives QTDP grant for UI device

Product Briefs

People in the News

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Feb. 14, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 14, 2025

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...